Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Pathophysiology of Alzheimer's Disease
- Susceptibility Factors in AD
- Apolipoprotein E
- The ApoE ε4 Allele and Other AD Risk Factors
- The Pharmacogenomics of AD
- The Influence of Metabolizing Enzymes on Drug Safety and Efficacy in
Alzheimer's Disease
- The Influence of Genetic Variation on Drug Efficacy in Alzheimer's
Disease
- Emerging Drug Targets in AD
- Amyloid Plaques
- Anti-Aβ-42 Vaccine Strategies
- Secretase Inhibitors
- γ-Secretase Modulators
- Anti-Aβ-42 Fibrillization Strategies
- RAGE Inhibitors
- Targeting Beta Amyloid
- Neurofibrillary Tangles
- GSK3-β Inhibitors
- Cdk-5 Modulators
- Targeting the Tau Protein
- Glucose Metabolism
- Other Targets
- NMDA Receptor
- Luteinizing Hormone
- Nerve Growth Factor
- Outlook for Emerging AD Targets
- Bibliography
Tables
- 1. Genes Associated with Familial Alzheimer's Disease
- 2. Select Susceptibility Genes in Late Onset Alzheimer's Disease
- 3. Select Collaborations in Alzheimer's Disease Pharmacogenomic Projects
- 4. Select Mutations in the CYP2D6 Gene
- 5. Select Drugs in Development Target Beta-amyloid Plaques
- 6. Advantages and Disadvantages of Active and Passive Vaccination
- 7. Select GSK3-β Inhibitors in Development Targeting Neurofibrillary
Tangles
- 8. Select Drugs in Development Against Other AD Targets
Figures
- 1. Amyloid Plaques and Neurofibrillary Tangles in Alzheimer's Disease
- 2. Normal and Pathogenic Cleavage of Amyloid Precursor Protein
- 3. Susceptibility Factors in Alzheimer's Disease
- 4. Sites of Action of Select Alzheimer's Disease Drugs
|
Related Report
|
View Cart
